Episode 190 - July 24, 2026

<p>On this week&#39;s episode, Josh Schimmer, Brian Skorney, Eric Schmidt, and Brad Loncar kick off with IPOs and raises, including Scribe&#39;s IPO, the first preclinical biotech IPO since the COVID era, which priced in a modest but upsized deal. The group also covers Mentari&#39;s additional $200 million raise ahead of its reverse merger with InMed, leading the co-hosts to question if reverse mergers are a positive for biotech or a worrisome trend. Next, the group turns to Colossal Biosciences&#39; talks to raise at a $20–30 billion valuation, prompting a broader question of what counts as biotech and where the industry&#39;s roots lie. The conversation turns to a recap of BiotechTV&#39;s inaugural U.S. Science Summit, where a central theme was the need to better explain biotech&#39;s work to the general public. The co-hosts then cover the fallout at Immix, whose CMO (hired in March 2025) turned out to be a fugitive on the run; the company disclosed the news in an 8-K, as they believed it not to be a material event. In data news, Dyne&#39;s Z-rostudirsen received FDA acceptance and priority review for DMD. The episode concludes with a discussion on policy, debating whether upcoming FDA adcomms for Replimune and Capricor signal a shift under new leadership. *This episode aired on July 24, 2026.</p>